Skip to content

In-Home Use Study to Evaluate Use of an Intimate Health Product in Females

A Single-blind, Multi-center, In-home Use Study to Evaluate Sexual Enhancement Effects of Product PD-F-5394 in Females

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00778934
Enrollment
79
Registered
2008-10-24
Start date
2007-12-31
Completion date
2008-04-30
Last updated
2011-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coitus

Brief summary

The purpose of this study is to evaluate the effects of an intimate health product on sexual experience in females.

Detailed description

Study to evaluate consumer perceptions of a cosmetic intimate health product on sexual experience in females, using a validated psychometric questionnaire.

Interventions

OTHERIntimate Health Gel

Intimate Health Gel

Sponsors

Johnson & Johnson Consumer and Personal Products Worldwide
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Normal, healthy females \>18 years of age * In committed heterosexual relationship for \>6months * Of adequate sexual functioning * On acceptable method of birth control

Exclusion criteria

* Pregnant or breastfeeding * Allergy to product ingredients * Irritation or infection in genital area * Unstable or uncontrolled medical condition

Design outcomes

Primary

MeasureTime frame
To assess the effect of product on sexual enhancement by comparing baseline questionnaire responses to the end of study questionnaire responsesEnd of study (3 weeks after baseline visit)

Secondary

MeasureTime frame
Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.throughout duration of the study (+ 30 days for spontaneously reported SAEs)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026